Archives: Antitrust

Subscribe to Antitrust RSS Feed

Unique Considerations in Healthcare M&A Part 3 – Closing/Post-Closing

Because the healthcare industry is heavily regulated and complex, most healthcare deals involve a sign-then-close structure; that is, they have a period of time between signing the agreement and the closing date. This built-in period after signing the purchase agreement gives the parties time to obtain necessary approvals or perform necessary pre-closing covenants.… Continue Reading

Unique Considerations in Healthcare M&A Part 2 – Negotiation/Drafting

As with any transaction, a healthcare deal typically starts with a Letter of Intent (“LOI”) or Term Sheet to outline the base agreements on the business deal. The LOI or Term Sheet should include not only the purchase price (or range), purchase price adjustments, payment terms, closing conditions, confidentiality, exclusivity, and other common items, but … Continue Reading

UPDATE: FTC victory creates challenge for physician acquisitions

The U.S. Court of Appeals for the 9th Circuit affirmed a lower court’s findings Feb. 10, 2015, that the acquisition by St. Luke’s Health System (“St. Luke’s”) of Saltzer Medical Group (“Saltzer”), a physician group consisting mostly of primary care physicians, violated Section 7 of the Clayton Act. This is the first case in which … Continue Reading

Unique Considerations in Healthcare M&A Part 1 – Due Diligence

Due diligence is often perceived as a mundane part of the mergers & acquisitions (M&A) process, but its importance in healthcare transactions is critical. Due diligence is one of the first steps of any transaction and involves a buyer undertaking an in-depth examination of the target to evaluate the business and uncover potential issues or … Continue Reading

Husch Blackwell's Turner speaks at AHLA Fundamentals program

The American Health Lawyers Association (AHLA) Fundamentals of Health Law conference, Nov. 12-14 in Chicago, featured Husch Blackwell Partner Cori Turner as a speaker and key member of the planning committee. The conference primarily focused on ensuring attendees gained an understanding of laws and regulations for the health law industry, including Stark and Anti-Kickback, False … Continue Reading

FDA Bars Generic “Copycat” OxyContin: Will Efforts to Limit Abuse of the Painkiller Also Limit Competition?

On April 16, in a win for Purdue Pharma, the maker of OxyContin, the FDA issued a decision approving updated labeling for Purdue’s reformulated, abuse-resistant OxyContin tablets. The decision places drug makers on notice that the FDA will not accept or approve any abbreviated new drug applications (generics) that rely upon the agency’s December 1995 … Continue Reading

Recent Antitrust Settlement Signals Regulators’ Willingness to Challenge Relatively Small Provider Consolidations

The FTC recently provided yet another warning to healthcare organizations that they must take the time to analyze potential antitrust implications when considering an acquisition or consolidation.  On August 6, the FTC  and Nevada Attorney General announced the filing of a lawsuit and proposed consent decrees settling litigation filed against Renown Health, the largest hospital provider in … Continue Reading

The U.S. Supreme Court Grants Cert in FTC v. Phoebe Putney Health System, Inc. to Determine the Breadth of the State Action Antitrust Immunity Doctrine

On June 25, 2012, the U.S. Supreme Court granted the Federal Trade Commission’s request for certiorari review in FTC v. Phoebe Putney Health System, Inc., a hospital merger case on appeal from the U.S. Eleventh Circuit Court of Appeals and the U.S. District Court for the Middle District of Georgia. At issue in the case … Continue Reading